statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Analyst Scoreboard: 4 Ratings For VYNE Therapeutics

Latest Ratings for VYNE
 DateFirmActionFromTo Dec 2021HC Wainwright & Co.AssumesBuy May 2021HC Wainwright & Co.MaintainsBuy Oct 2020HC Wainwright & Co.MaintainsBuy
 View More Analyst Ratings for...

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ( VYNE or the Company ), a clinical-stage biopharmaceutical company focused on developing proprietary...

VYNE Therapeutics Inc. (NASDAQ:VYNE) Sees Significant Drop in Short Interest

VYNE Therapeutics Inc. (NASDAQ:VYNE  Get Free Report) saw a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 35,800...

Vyne Therapeutics files for $250M mixed shelf

Vyne Therapeutics files for $250M mixed shelf...

Recap: VYNE Therapeutics Q4 Earnings

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

2023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful financing with a syndicate of leading institutional...

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

Oral presentation on March 7, 2024 will review positive safety and efficacy data for novel BET inhibitor VYN201 BRIDGEWATER, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq...

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ( VYNE or the Company ), a clinical-stage biopharmaceutical company developing proprietary, innovative...

Insider Buyers At VYNE Therapeutics Recover Some Losses, But Still Down US$35k

Insiders who bought US$125.5k worth of VYNE Therapeutics Inc. ( NASDAQ:VYNE ) stock in the last year have seen some of...

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

VYN201 demonstrated positive effect on key biomarkers relevant to vitiligo Data supports VYN201's rapid onset of action and previously announced positive clinical resultsProgram is on track for Phase...

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercializes solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company was founded in October 2011 and is headquartered in Bridgewater, NJ.

Volume	13,237.00
52-Wk High	$6.79
52-Wk Low	$1.57

VYNE VYNE Therapeutics Inc

About

Feed

News

Sentiment

Fundamentals